# US 11,441,198 B2 · Compositions and methods for providing a prognosis for influenza infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,441,198 B2
- Document ID: US11441198B2
- Status: Granted
- Kind: B2
- Application number: 16/312,958
- Filed: 2017-06-30
- Published: 2019-10-24
- Granted: 2022-09-13
- Earliest claimed: 2016-07-01
- Assignees: Versitech Limited
- Applicants: Versitech Limited
- Inventors: Kai Wang Kelvin To; Jie Zhou; Johnson Yiu-Nam Lau; Kwok-Yung Yuen
- Web page: https://patentgrep.com/patent/US11441198B2

## CPC

- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- A61P 31/16: for influenza or rhinoviruses
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 33/56983: {Viruses}
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Compositions and methods are described that provide prognostic determination of the severity of influenza infection based on the PDE3A status of an individual. Impaired PDE3A function is associated with severe symptoms on contracting influenza. Specific SNP mutations are identified that are associated with impaired PDE3A function, and primers and kits are provided that permit identification of these SNPs. Such information can also be combined with other patient data.

## Claims

### Claim 1

A method of treating influenza in an individual, comprising:
i) obtaining a sample from the individual;
ii) determining that the individual carries a PDE3A mutation associated with severe influenza disease,
wherein the mutation comprises one or more of T at rs7314545, T at rs6487131, and G at rs6487132; and
iii) treating the individual determined to carry the PDE3A mutation(s) with an antiviral compound effective against influenza.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of blood, saliva, a nasal swab, and a cheek swab.

### Claim 3 (depends on 1)

The method of claim 1, comprising performing a test characterizing a PDE3A gene product on at least a portion of the sample.

### Claim 4 (depends on 1)

The method of claim 1, comprising a polynucleotide amplification step.

### Claim 5 (depends on 1)

The method of claim 1, comprising an immunochemical assay.

### Claim 6 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in reduced PDE3A gene product activity.

### Claim 7 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in reduced PDE3A gene transcription.

### Claim 8 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in reduced PDE3A gene translation.

### Claim 9 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in an impaired capacity for viral clearance and higher viral replication during an influenza infection compared to a control without the PDE3A mutation.

### Claim 10 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in elevated proinflammatory cytokine expression during an influenza infection compared to a control without the PDE3A mutation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the proinflammatory cytokine is selected from the group consisting of IL-6 and IL-32.

### Claim 12 (depends on 1)

The method of claim 1, wherein the PDE3A mutation results in reduced antiviral and anti-inflammatory activities during an influenza infection compared to a control without the PDE3A mutation.